希少疾患からの臨床データを活用して、他の疾患の医薬品承認をサポート

出典非定型溶血性尿毒症症候群（aHUS）は、全身の細い血管に異常な血栓形成を引き起こし、腎不全、他の臓器障害、早死にを引き起こす超希少な遺伝病です。このプロジェクトの開始時点では、FDAが承認したaHUSの治療法はありませんでした。Furthermore, as only a few thousand aHUS patients are diagnosed each year, recruiting enough participants to conduct clinical trials was difficult.

However, the FDA had approved a humanized monoclonal antibody (mAb), eculizumab, to treat a related, rare, life-threatening disease – paroxysmal nocturnal hemoglobinuria (PNH), which is characterized by destruction of red blood cells and excessive blood clotting. Both aHUS and PNH symptoms result from chronic, uncontrolled complement system activation. Knowing eculizumab’s mechanism of action for PNH suggested that it could confer clinical benefit in aHUS.

ソリューション

後期臨床

Therapeutic specialty

希少疾患

Products

ファーマコメトリクス

A population PK model for eculizumab, which had been previously constructed for adult PNH patients, was repurposed to determine dosing for aHUS patients. The mAb’s PK/PD relationship in PNH was also leveraged to determine drug exposure and inform pediatric aHUS dosing.

Two small Phase II studies and a retrospective observational study were conducted, involving just 57 aHUS patients. PK/PD modeling of those data was used to determine the dose- response-effect relationships for two surrogate endpoints. Then, trial simulations based on that modeling were used to determine the best dosing for pediatric and adult patients with aHUS.

Patients with aHUS who were treated with eculizumab had improved platelet counts and other blood parameters and better kidney function with some patients no longer requiring plasmapheresis. The FDA approved eculizumab to treat both adult and pediatric aHUS patients.

Trial simulations were used to determine the best dosing for pediatric and adult aHUS patients.

Headquartered in the U.S., our client has been a leader in the discovery, development, and commercialization of medicines for rare diseases for nearly 30 years. Its research efforts focus on novel molecules and targets in the complement cascade, and it operates in more than 50 countries.